• News
• Contact Us
• Home

Pioneering Science Protected by Patents and Process

• Science & Technology
• OncoVAX® Treatment Schedule
• Scalable Production
• Patent Portfolio
• Science Due Diligence

Strong novel patent portfolio

Patent coverage for patient-specific tumor vaccines and human monoclonal antibodies.

• The Vaccinogen portfolio includes twenty (20) approved or issued US patents; and
• Rapid follow-on products based upon experience from pivotal study in
  colon carcinoma and Phase I/II data in Stage III colon carcinoma, renal
  carcinoma and melanoma.